Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors  by Jolly, Clare
Virology 411 (2011) 251–259
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roReview
Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced
restriction factors
Clare Jolly ⁎
Wohl Virion Centre and MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, W1T 4JF, UK⁎ Fax: +44 207 679 9555.
E-mail address: c.jolly@ucl.ac.uk.
0042-6822/© 2010 Elsevier Inc.
doi:10.1016/j.virol.2010.12.031
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 10 December 2010
Returned to author for revision
13 December 2010
Accepted 17 December 2010
Available online 17 January 2011
Keywords:
HIV
Retrovirus
Virological synapse
Restriction factor
Innate immunity
Interferon
Tetherin
BST-2
VpuIt has been known for some time that retroviruses can disseminate between immune cells either by
conventional cell-free transmission or by directed cell-to-cell spread. Over the past few years there has been
increasing interest in how retroviruses may use cell-to-cell spread to promote more rapid infection kinetics
and circumvent humoral immunity. Effective humoral immune responses are intimately linked with innate
immunity and the interplay between retroviruses and innate immunity is a rapidly expanding area of research
that has been advanced considerably by the identiﬁcation of cellular restriction factors that provide barriers to
retroviral infection. The effect of innate immunity and restriction factors on retroviral cell-to-cell spread has
been comparatively little studied; however recent work suggests this maybe changing. Here I will review
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Retroviruses are a diverse family of enveloped RNA viruses that
encompass a number of medically important human pathogens
including the Human Immunodeﬁciency Virus (HIV), which alone
has accounted for approximately 25 million deaths worldwide. Over
the past decade huge scientiﬁc and medical endeavour has beenfocussed towards understanding the biology of viral pathogenesis
and transmission between and within hosts. Like a number of other
mammalian viruses, retroviruses can disseminate between suscepti-
ble cells either by cell-free infection or by direct cell-to-cell spread
(reviewed in (Sattentau, 2008)). Retroviruses spread directly be-
tween cells by taking advantage of their immunotropic properties to
infect CD4+ T cells, macrophages and dendritic cells that inherently
form intimate, dynamic and transient contacts (Jolly and Sattentau,
2004). In this way, retroviruses can co-opt specialized properties of
immune cells that normally operate during intercellular communica-
tion such as antigen presentation and T cell activation to promote
their dissemination between cells.
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(HIV-1) and HTLV-1 (Human T-lymphotropic Virus Type-1) predom-
inantly takes place at specialized contact-induced structures known
as virological synapses (VS) that act as “hot-spots” for virus trans-
mission (Igakura et al., 2003; Jolly et al., 2004; Jolly and Sattentau,
2002; McDonald et al., 2003). VS were so named because of their
resemblance to immunological synapses (IS) and the term VS was
coined to describe a speciﬁc membrane receptor architecture that
evolves following intimate contact between a HIV-infected T cell and
an uninfected target T cell (Jolly and Sattentau, 2002). Cell-to-cell
spread of HIV-1 at synapses is a generalized feature of viral
dissemination and VS have been described between infected and
uninfected CD4+ T cells (Jolly et al., 2004), betweenmacrophages and
CD4+ T cells (Gousset et al., 2008; Groot et al., 2008) and between
virus-exposed dendritic cells and CD4+ T cells (McDonald et al.,
2003). This phenomenon is not restricted to HIV-1, and one of the ﬁrst
VS described was that of HTLV-1 (Igakura et al., 2003). Longer-range
intercellular transmission of HIV-1 between T cells has also been
observed along cellular projections known as membrane nanotubes
(Sowinski et al., 2008), while the related retrovirus murine leukeamia
virus (MLV) utilizes virus-induced ﬁlopodia for efﬁcient dissemina-
tion (Sherer et al., 2007). The relative contribution of cell-to-cell
spread at VS, membrane nanotubes and via cell-free infection is
difﬁcult to quantify, but in vitro culture systems have demonstrated
that cell-cell spread is the predominant mode of HIV-1 dissemination
and this is mostly via VS (Sourisseau et al., 2007). At present there is
considerable effort towards delineating retroviral protein trafﬁcking
in infected cells during cell-to-cell spread and understanding the
molecular regulators of transmission in both donor and target cells
(Arrighi et al., 2004; Chen et al., 2007; Gousset et al., 2008; Groot et al.,
2008; Hubner et al., 2009; Rudnicka et al., 2009; Turville et al., 2004;
Igakura et al., 2003; McDonald et al., 2003; Barnard et al., 2005; Jolly
et al., 2004, 2007a,b; Jolly and Sattentau, 2005, 2007; Llewellyn et al.,
2010; Nejmeddine et al., 2005, 2009) and readers are directed to a
recent series of comprehensive reviews that consider this in detail
(Feldmann and Schwartz, 2010; Jolly, 2010; McDonald, 2010; Mothes
et al., 2010; Nejmeddine and Bangham, 2010; Sattentau, 2010; Waki
and Freed, 2010).
In the context of viral pathogenesis, direct cell-to-cell transmission
is likely to confer a number of advantages for retrovirus compared
to classical cell-free infection. Firstly, cell-to-cell spread increases
infection kinetics by directing virus assembly and budding to sites of
cell-to-cell contact andmay be one or more orders of magnitudemore
efﬁcient than equivalent cell-free infection (Dimitrov et al., 1993;
Mazurov et al., 2010; Chen et al., 2007; Martin et al., 2010; Sato et al.,
1992; Sourisseau et al., 2007). This is achieved by obviating the rate-
limiting step of extracellular diffusion that is required of cell-free virus
to ﬁnd a susceptible target cell. Furthermore, polarizing virus budding
towards sites of cell-to-cell contact at which viral entry receptors are
clustered increases the number of potentially productive transmission
events and increases the likelihood of productive infection.
Secondly, it has been hypothesised that cell-to-cell spread of
retroviruses could provide a replicative advantage to the virus by
limiting exposure of particles to neutralizing antibodies (Martin
and Sattentau, 2009). It has generally been assumed that cell-to-cell
spread of retroviruses at VS might allow escape from neutralizing
antibodies either by limiting the window of opportunity for antibody
to engage viral antigens, or by providing a relatively protected domain
at cell-to-cell interfaces that could physically exclude the relative bulk
of antibodies from gaining access to virions before they attach and
enter to target cells. Whether VS protect retroviruses from humoral
immunity is still unclear and there are conﬂicting reports on this in
the literature (Chen et al., 2007; Ganesh et al., 2004; Martin et al.,
2010; Massanella et al., 2009). Possible explanations for disparate
results have been considered elsewhere (Sattentau, 2010) and so will
not be elaborated in detail here.Humoral immunity to human retroviruses such as HIV-1, the
causative agent of Acquired Immune Deﬁciency Syndrome is of
particular interest within the context of cell-to-cell spread because
of the implications of immune evasion for vaccine design and viral
pathogenesis. The innate immune response is intimately linked to the
generation of an effective adaptive immune response. Thus retroviral-
induced innate immune responses may have a direct impact on cell-
to-cell transmission but may also modulate adaptive immunity and
thereby control of viral infection. The role of innate immunity during
cell-to-cell spread of retroviruses has only recently been explored;
however, it is increasingly apparent that harnessing innate immunity
might provide a crucial opportunity to tackle HIV-1 at some of the
earliest steps of infection, and that the interplay between HIV-1 and
innate immunity has important implications for disease pathogenesis
(Borrow et al., 2010). In the context of HIV-1 cell-to-cell spread the
balance between viral suppression and enhancement by innate im-
mune responses is intriguing, although relatively little studied. Here I
will discuss some recent insights into cell-to-cell spread and innate
immunity and consider how the interplay between HIV-1 and innate
effectors may modulate cell-to-cell dissemination. I will focus
predominantly on HIV-1, but it is likely that some aspects of innate
immunity and HIV-1 will be applicable to other retroviruses.
Recognition of HIV-1 by innate immune receptors during
cell-to-cell spread
At the earliest time points after infection, before adaptive
immunity has been activated, the innate immune system provides
the ﬁrst line of antiviral defences and alerts the wider immune system
of challenge. An important feature of innate immunity that facilitates
such rapid response is the recognition of generalized pathogen-
associated molecular patterns (PAMPS). This is mediated by via a
range of pattern recognition receptors (PRR) including C-type lectins
(CLR), Toll-like receptor (TLRs) and cytosolic sensors such as NOD-like
receptors and the retinoid acid-inducible gene (RIG) like receptors
RIG-I andMDA5. Recognition of ubiquitousmicrobial patterns leads to
signal transduction, activation of the transcription factors such as NF-
κB, mitogen-activated protein kinase (MAPK) and interferon regula-
tory factor (IRFs), and culminates in secretion of proinﬂammatory and
immunomodulatory cytokines such as type-1 interferons (interferon-
α and interferon-β). TLRs are located at the cell surface or in endocytic
compartments and collectively recognize a range of viral and bacterial
ligands including hydrophobic molecules, glycoproteins, bacterial
cell wall components and nucleic acid, the latter being a particularly
potent activator. To date, 10 different TLRs have been identiﬁed in
humans. In addition, other receptors such as C-type lectins and
scavenger receptors on cell surfaces can act as TLR coreceptors and
bind to microbes via PAMPs which culminates in a signaling cascade
that alerts the wider immune system of danger. In the context of
HIV-1, a number of steps in the viral life cycle have been shown to
activate immunity via PRR recognition including attachment of the
HIV-1 envelope glycoprotein (Env) subunit gp120 by the C-type lectin
DC-SIGN (Dendritic Cell-Speciﬁc Intercellular adhesion molecule-3-
Grabbing Non-integrin) (Gringhuis et al., 2010); TLR7/8-mediated
detection of HIV-1 RNA (Beignon et al., 2005; Heil et al., 2004; Meier
et al., 2007) andmore recently the identiﬁcation of an intrinsic dendritic
cell sensor that detects the interaction between newly synthesized HIV-
1 capsid and cylophilin A and activates the transcription factor IRF3
(Manel et al., 2010). Interestingly, cell-free HIV-1 infection may escape
innate immune detection in some situations and it has been proposed
that that macrophages lack a functional PRR for HIV-1 therefore
attenuating NF-κB and IRF3 activation and type-1 interferon induction
(Noursadeghi et al., 2009; Tsang et al., 2009).
So far, most studies examining innate immune recognition of HIV-
1 have utilized cell-free virus or viral constituents, and characterized
their effects on dendritic cells and macrophages. Therefore, it is
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same innate immune sensors as cell-free infection or whether it
bypasses or activates different checkpoints for innate immune
activation. It is reasonable to assume that infection may have diverse
consequences for the cell depending upon whether viral transmission
was mediated by cell-free or cell-to-cell spread. For example, it has
been suggested that HIV-1 entry during cell-to-cell contact may
involve endocytosis (Blanco et al., 2004; Chen et al., 2007; Hubner et
al., 2009) rather than fusion at the plasma membrane. Although the
concept of productive infection via endocytosis remains controversial,
if it is correct then the use of different modes of virus entry (e.g.,
fusion at the plasma membrane vs. endocytosis) may mean that viral
constituents could be differentially presented or protected from
innate immune receptors. Furthermore, polarization of viral egress
towards target cells during cell-to-cell spread increases the amount of
viral protein and nucleic acid that enters the target cell that may in
turn increase viral antigen above a critical threshold to trigger an
innate response. Notably, the Greene lab have very recently reported
that the accumulation of abortive reverse transcription intermediates
in resting CD4+ T cells following contact with infected cells activates
proinﬂammatory and apoptotic host defences by the persistent
exposure to cytoplasmic DNA, resulting in death of these non-
productively infected cells (Doitish et al., 2010). Intriguingly, it was
noted that indirect killing was dependent on close cell-to-cell contact
and was mediated by transmitting HIV-1 virions but not cell-
associated Env (Doitish et al., 2010). This effect could be recapitulated
by spinoculation of cell-free virus onto cells, suggesting that the
quantity of virus transferred to resting T cells during cell-to-cell
contact results in an accumulation of defective cytoplasmic viral DNA
triggering an IRF-3-dependent innate immune response by a TLR-
independent mechanism (Stetson and Medzhitov, 2006). It will be
informative to determine to what extent cell-to-cell spread of HIV-1
results in cell death rather than productive infection in activated and
resting T cells when virus is transmitted across the different types of
VS and how this is regulated. For example mRNA encoding TLR 1, 2, 3,
4 5, 7 and 9 have been detected in human CD4+ T cells (Holm et al.,
2009; Xu et al., 2005). TLR activation can functionally result in
cytokine secretion from T cells but we do not yet know if cell-to-cell
spread triggers TLR recognition in CD4+ T cells. It is also unclear if
dendritic cells and macrophages can serve as target cells rather than
donor cells during cell-to-cell spread. DCs and macrophages efﬁcient-
ly transmit infectious HIV-1 to susceptible CD4+ T cells, but whether
infected T cells can transmit virus back to DCs and macrophages, is
unknown. This is an important question since it is this lineage of cell,
rather than T lymphocytes, that dominate innate immune type-1
interferon secretion in vivo. It is clear that more work is needed in this
area to address these and other questions.
Modulating innate immunity to promote cell-to-cell spread
of HIV-1
As the ﬁrst line of the cellular innate response to infection,
patrolling sentinel cells such as plasmocytoid and myeloid dendritic
cells (pDC andmDC, respectively), Langherhan cells andmacrophages
are all poised to detect and engage foreign invaders. Paradoxically,
some of these cells are also among the earliest targets for HIV-1 in
vivo. Whether cell-to-cell spread triggers or suppresses antiviral
responses, either virus-induced or coincidental, that the virus might
use to its own advantage is an interesting proposition and number
of recent studies have started to explore how HIV-1 may modulate
innate immunity speciﬁcally during cell-to-cell spread. Mature
myeloid DCs in particular are thought to play a key role in HIV-1
transmission between hosts by capturing incoming virions at mucosal
surfaces and disseminating virus directly to CD4+ T cells by cell-to-
cell transmission, thereby allowing HIV-1 to take advantage of the
inherent response of activated mDCs to migrate to secondarylymphoid organs and interact intimately with T cells. DCs do not
usually become productively infected with HIV-1 even in vitro, al-
though they do express the appropriate HIV-1 entry receptors (CD4
and a chemokine co-receptor) and it generally held that productive
infection by HIV-1 is a property of immature mDCs (Turville et al.,
2004). As a consequence, dissemination of HIV-1 bymaturemDCs to T
cells is considered to mostly occur in trans - a process by which HIV-1
virions are captured by receptors expressed on the surface of mDCs
and transferred directly to T cells during intimate cell-to-cell contact.
This occurs by capture of HIV-1 particles by DC-SIGN present on the
surface of DCs (Geijtenbeek et al., 2000) that recognise moieties on
the Env subunit gp120, although other receptors can also mediate
trans-infection (de Witte et al., 2007a; Lambert et al., 2008; Turville
et al., 2001). Once the HIV-1-DC-SIGN complex is formed it may
remain at the plasma membrane or become internalized into a
partially protective endocytic compartment (thus avoiding complete
degradation of infectious virus) and subsequently trafﬁcked to the
cell-to-cell junctions during VS formation (Geijtenbeek et al., 2000;
McDonald, 2010; McDonald et al., 2003). By contrast, HIV-1 capture
by Langerhans cells expressing the receptor Langerin results in
degradation of virus (de Witte et al., 2007b). To date, most work has
focussed on conventional mDCs and it is not clear whether pDC can
also capture HIV-1 and transmit virus to T cells and this is no doubt
complicated by the fact that pDC are more difﬁcult to work with and
comprise only 1% of peripheral blood mononuclear cells (PBMCs);
however, there are reports that the related retrovirus HTLV-1 can
infect pDCs (Colisson et al., 2010; Hishizawa et al., 2004) and
so parallels to HIV-1 may exist.
DC-SIGN is a PRR and a C-type lectin that normally binds
carbohydrate-containing ligands and initiates a response to foreign
antigen via activating Toll-like receptors (Robinson et al., 2006).
Insight into how HIV-1 may modulate signaling via DC-SIGN to
promote cell-to-cell spread has come from recent studies investigat-
ing the DC-SIGN signalosome. Using gene expression proﬁling and
phosphoproteomics, Hodges et al., observed that HIV-1 interaction
with DC-SIGN triggers a signaling pathway leading to activation of
LARG and increased RhoA-GTPAse activity and that this is necessary
for efﬁcient DC-T cell VS formation and cell-to-cell spread, possibly by
RhoA modulation of exocytosis from DCs or regulation of actin
dynamics (Hodges et al., 2007). HIV-1 induced DC-SIGN activation
also synergises with TLR8 activation by HIV-1 ssRNA for recruitment
of transcription factors required for full-length viral transcript syn-
thesis under conditions where DCs do become productively infected
and transmit virus to T cells in cis (Gringhuis et al., 2010). In these
ways, HIV-1 can take advantage of binding to a PRR to direct
downstream signaling events that favour cell-to-cell spread.
How does HIV-1 avoid degradation when internalized into DCs
and transmit efﬁciently to T cells? Recent evidence suggests that a
contributing factor maybe the ability of HIV-1 to down-regulate the
autophagy pathway in cells. Autophagy is a specialized lysosomal
degradation pathway of self-digestion that is necessary for correct
antigen processing and presentation by MHC class II and for the
delivery of TLR ligands to endosomes for innate immune activation
(Virgin and Levine, 2009) and there is evidence that this pathway can
be hijacked by viruses to promote pathogenesis (Kudchodkar and
Levine, 2009). HIV-1 gp120 binding to CD4 on DCs has been shown to
down-regulate autophagy in DCs bymTor activation and regulate cell-
cell spread in trans (Blanchet et al., 2010). Inducing autophagy with
rapamycin also inhibits DC-T cell transmission by virus-pulsed DCs
(Blanchet et al., 2010) suggesting that regulating the autophagy
pathway may play a key role in early HIV-1 spread by diverting virus
from antigen processing pathways and allowing infectious virus to
remain within the DC for subsequent delivery to the VS. Cell-free HIV-
1 infection of macrophages also inhibits rapamycin-induced autop-
hagy (Van Grol et al., 2010) and increases HIV-1 cell-free yield (Espert
et al., 2006; Kyei et al., 2009); however whether this affects cell-to-
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down-regulates autophagy in CD4+ T cells during productive
infection. By contrast to DCs however, CD4-Env binding on T cells
was found to activate autophagy, but this was overridden by virus
infection although the effect on cell-to-cell spread was not elucidated
(Espert et al., 2006).
In addition to potentially directly affecting infectious virus
trafﬁcking in cells, another consequence of loss of autophagosome is
seen in HIV-1 exposed DCs that display altered TLR4 and TLR8
responses (Blanchet et al., 2010). The direct association of HIV-1 with
DC-SIGN also has consequences for TLR4 signaling leading to
increased expression of IL-6, IL-10 and IL-12 with presumed down-
stream effects on Th differentiation (Gringhuis et al., 2009) and
possible consequences for viral dissemination. There is also evidence
that HIV-1 limits DC maturation with consequences for CD4+ T cell
proliferation, cytokine secretion and adaptive immunity (Kawamura
et al., 2003). Thus it appears that the ability of HIV-1 to modify the
cellular autophagy pathway in immune cells and thus avert innate
and adaptive immunity may be at the heart of efﬁcient cell-to-cell
spread and dissemination of HIV-1 from mucosal surfaces, thereby
allowing the virus to establish a foothold during early transmission
and contributing to subsequent spread between target cells and
cellular reservoirs.
Cell-to-cell spread and interferon-induced, antiviral
restriction factors
The induction of type-1 interferon upregulates expression of a
large number of interferon inducible genes (ISGs), some of whichFig. 1. Scanning electron micrographs (SEM) showing the characteristic tetherin-mediated re
1 (ΔVpu- HIV-1) and B) Jurkat T cells infected with Vpu-expressing WT HIV-1 (WT HIV-1) w
hand panels show higher magniﬁcation of the T cell plasma membrane arrows, scale bar=
tethered at the plasma membrane of cells infected with Vpu-defective virus (upper panels)encode proteins with direct antiviral properties. One of the most
important of these within the context of retroviral dissemination is a
group of proteins with potent antiviral properties known collectively
as “restriction factors”. Restriction factors are cellular proteins that are
constitutively expressed or induced by type-1 interferon and are able
to limit viral replication by targeting speciﬁc steps of the retroviral
viral life cycle (reviewed in (Wolf and Goff, 2008)) rendering cells less
permissive or non-permissive to infection. In the context of human
retrovirus infection three major restriction factors have now been
described – APOBEC3G/F (apolipoprotein B mRNA editing complex
catalytic subunit) (Sheehy et al., 2002); TRIM5 (Tripartite motif-
containing protein 5) (Stremlau et al., 2004) and tetherin (also known
as BST-2, CD317 and HM1.24) (Neil et al., 2008). The importance of
innate restriction factors to infection is highlighted by the fact that
lentiviruses contain genes encoding for accessory proteins speciﬁcally
to antagonize restriction - Vif that inhibits APOBEC3-mediated
cytidine deamination of viral transcripts, and in the case of HIV-1
Vpu that overcomes tetherin-mediated inhibition of nascent particle
release from the plasma membrane of virus-producing cells (Fig. 1).
Restriction factors are of particular interest to retroviral pathogenesis
because they exert such potent inhibition of viral replication and are
upregulated in some cell types by interferon, suggesting that they
form part of the innate antiviral defence against viral challenge. This
has raised the possibility of harnessing innate immunity and type-1
interferon induction to upregulate endogenous restriction factor
expression in vivo, or possibly using gene-therapy to introduce
restriction factors from another species that may be resistant to
antagonism by viral proteins or that may have restrictive properties
that do not exist in equivalent proteins from the host species.striction of HIV-1 release from T cells. A) Jurkat T cells infected with Vpu-defective HIV-
ere imaged by SEM at 7 days post-infection. Left hand panel scale bar=500nm. Right
200nm. Some example virions are indicated with arrows. Note that more virions are
.
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other enveloped viruses has been a very active area of research for a
number of years (reviewed in (Neil and Bieniasz, 2009;Wolf and Goff,
2008)). By contrast, less is known about whether restriction factors
are inhibitory during cell-to-cell spread, although some studies are
beginning to address these questions.
TRIM5 and APOBEC
When considering the site of action of restriction factors in the
context of cell-to-cell spread it is helpful to consider restriction factors
in two groups, divided on the basis of which steps they target in the
cell-free retroviral life cycle: those that block HIV-1 exit from the virus
transmitting donor cell (e.g., tetherin and ISG15) and those that may
act to restrict the early steps of virus infection (e.g., APOBEC3 and
TRIM). Regarding restriction factors that target early steps (pre-
integration) in the retroviral life cycle once it enters a target cell, the
pertinent question is whether the restriction factor is saturable and
therefore whether cell-to-cell spread may overwhelm the existing
cytoplasmic pool of protein laying in wait for viral invaders. Despite
the uncertainty about the mechanism of productive entry during cell-
to-cell spread (endocystosis or fusion at the plasma membrane
fusion), restriction factors target steps of the retroviral life cycle
(uncoating, reverse transcription and integration) that are essential
for successful proviral integration and must be achieved for produc-
tive infection to ensue.
Rhesus TRIM5α is a potent inhibitor of HIV-1 infection that
restricts at different stages of the viral life cycle probably by
promoting capsid disassembly (Chatterji et al., 2006; Stremlau et al.,
2006), inhibiting reverse transcription (Stremlau et al., 2004) and
preventing integration (Anderson et al., 2006; Diaz-Griffero et al.,
2007; Wu et al., 2006). Notably, there is clear species speciﬁcity in
TRIM5 activity and HIV-1 is largely resistant to restriction by human
TRIM5 but is sensitive to restriction by TRIM5 from Old World
Monkeys (Stremlau et al., 2004). This has raised the possibility of
engineering human cells to express rhesus TRIM5 (rhTRIM) as a
therapeutic intervention to target HIV-1. Since human TRIM5 cannot
restrict HIV-1 the issue of cell-to-cell versus cell-free restriction was
addressed by engineering primary human CD4+ T cells to express
rhTRIM5 and investigating whether transmission of virus between
T cells was efﬁciently restricted (Richardson et al., 2008). Taking this
approach Richardson et al., reported that rhTRIM5 efﬁciently blocked
cell-free infection, but not infection mediated by cell-to-cell spread.
Moreover they observed that inhibition of HIV-1 spreading infection
in in vitro culture required rhTRIM5 to be expressed in both the virus-
producing cell and the target cell and rhTRIM5 was unable to inhibit
cell-to-cell spread unless expressed by the majority of cells in culture.
It has previously been suggested, albeit controversially, that TRIM5
can restrict the production infectious HIV-1 when expressed in the
producer cell (Sakuma et al., 2007) but this is unlikely to be the
mechanism of restriction of cell-to-cell transmission. It is most
likely that cytoplasmic TRIM5 in target cells can be saturated by the
increase in capsid that is transmitted during cell-to-cell spread and
so expression of rhTRIM5 in the donor cell allows rhTRIM to also
associate with capsid during virus production, thus tipping the scales
in favour of restriction upon entry into target cells.
Members of the APOBEC family of restriction factors are incorpo-
rated into nascent virions in the virus-producing cell that inhibit
retroviral infection in target cells by deaminating dC to dU in nascent
minus-strand DNA, resulting in G-to-A hypermutation (Harris et al.,
2003; Lecossier et al., 2003; Mangeat et al., 2003) thereby inhibiting
reverse transcription and integration (reviewed in (Albin and Harris,
2010). This is overcome by HIV-1 Vif that prevents packaging of
APOPBEC into particles during virus assembly in infected cells, in
part by proteasome-dependent degradation and/or possibly by direct
inhibition of encapsidation (reviewed in (Albin and Harris, 2010)).APOBEC is induced by type-1 interferon in macrophages but not
activated primary T cells or T cell lines (Koning et al., 2009; Refsland
et al., 2010; Stopak et al., 2007) and it has been suggested that within
the target cell APOBECs are unlikely to be strong inhibitors (Goujon
and Malim, 2010). To date no studies have addressed whether
APOBECs restrict cell-to-cell spread as efﬁciently as cell-free infection,
but it seems most likely that cell-to-cell spread would be similarly
sensitive to APOBEC-mediated DNA editing since there is no reason
why Vif should not exclude APOBEC encapsidation during de novo
virus assembly at the VS (Hubner et al., 2009), unless the rapid and
polarized assembly of virions temporally or spatially precludes
efﬁcient Vif activity for some reason. Further work is needed to fully
understand how APOBECs get incorporated into nascent virus. For
example, at what stage they encounter viral RNA, whether this may
differ between cell-free virus production or assembly at the VS, and
where Vif interacts with APOBEC in order to speculate about whether
cell-to-cell spread may be similarly susceptible to APOBEC-mediated
restriction in the absence of Vif, or whether some APOBEC may slip
through. In addition to TRIM5 and APOBECs it is very likely there are
other as yet undiscovered restriction factors that target post-entry
steps of HIV-1 infection in target cells (Goujon and Malim, 2010) and
further investigation of restriction of cell-to-cell spread is certainly
warranted.
Tetherin and ISG15
Evidence to date suggests that the general mechanism of assembly
and budding of retroviruses from productively infected CD4+ T cells
andmacrophages at the VS is the same as that of cell-free virus release
(Gousset et al., 2008; Groot et al., 2008; Hubner et al., 2009; Jolly et al.,
2004; Martin et al., 2010; Mazurov et al., 2010). Live cell imaging has
previously revealed de novo assembly of HIV-1 and MLV with
preferential viral assembly at the contact site (Hubner et al., 2009;
Jin et al., 2009). Retroviral cell-to-cell spread may also occur without
signiﬁcant de novo assembly via the transfer of infectious virions that
have budded through the plasma membrane but remain associated
with the cell surface by interactions with cellular proteins (Pais-
Correia et al., 2010; Sherer et al., 2010). It can postulated then that
restriction factors that target late steps in virus production in donor
cells might be similarly active at inhibiting viral egress during either
cell-free transmission or direct cell-to-cell spread. Conversely cell-to-
cell spread may saturate a restriction factor if it was not associated
with the VS at the right time and in sufﬁcient quantity. Moreover,
different mechanisms of cell-to-cell spread (e.g., de novo virus
production at cell-to-cell contacts versus lateral movement of
budding virus from distal membrane domains towards the VS) may
be susceptible to restriction while others may be less so. Two studies
have recently addressed this question and considered whether cell-
to-cell spread of HIV-1 between T cells is sensitive or resistant to
restriction by tetherin, with apparently conﬂicting results. Casartelli
et al. reported that tetherin inhibited cell-to-cell spread of HIV-1 and
that tetherin blocked productive transmission by reducing viral
fusigenicity and thus infectivity. Unusually large aggregates of virus
were transferred from tetherin-expressing HeLa donor cells to target
cells and this virus was less able to initiate productive infection
(Casartelli et al., 2010). By contrast, Jolly et al. found that productive
cell-to-cell spread of HIV-1 between T cells was not restricted by
endogenous tetherin expressed on donor T cells and infectious virus
was transmitted across the T cell VS resulting in productive infection
(Jolly et al., 2010). The observation that Vpu-defective virus is
transmitted as efﬁciently, if not more so thanWT virus is in agreement
with a number of previous studies (Gummuluru et al., 2000; Klimkait
et al., 1990; Schubert et al., 1995; Sourisseau et al., 2007; Strebel et al.,
1989; Terwilliger et al., 1989; Yao et al., 1993). Possible reasons for
the differences observed between our study and Casartelli et al. may
not be immediately obvious since both groups agree that tetherin is
256 C. Jolly / Virology 411 (2011) 251–259present at the T cell VS and that synapses appear to be form normally
in the presence of tetherin on the virus-producing cell (Casartelli
et al., 2010; Jolly et al., 2010). In both studies, cell-to-cell spread of
HIV-1 was interrogated in the presence or absence of Vpu using Vpu-
expressing or non-expressing virus: Vpu-defective virus does not
antagonize tetherin and results in the well-characterized budding
defect where nascent, proteolytically matured virions remain at-
tached to the surface of the virus-producing cell by membrane tethers
(Neil et al., 2008; Strebel et al., 1989; Van Damme et al., 2008). In the
presence of Vpu, tetherin activity is abrogated and the protein is
degraded via the proteasome (Gofﬁnet et al., 2010a; Mangeat et al.,
2009; Van Damme et al., 2008) and/or lysosome (Douglas et al., 2009;
Iwabu et al., 2009; Mitchell et al., 2009), but whether this results in
global down-regulation of tetherin from the plasma membrane, or
simple exclusion of tetherin from membrane regions that prevent
association with viral proteins is unclear. The ﬁndings of Casartelli
et al., and Jolly et al., may be somewhat reconciled by considering
the type of the donor cells used to examine cell-to-cell spread and
the chronicity of the infection, since the experimental assays were
broadly similar. It may be that in the presence of lower levels of
tetherin, such as is endogenously expressed on T cells (used by (Jolly
et al., 2010)), productive cell-to-cell spread can take place without
effective restriction (Fig. 2). Tetherin expressed on the surface of T
cells would be sufﬁcient to retain virions at the cell surface and in this
way mature infectious virus attached to the plasma membrane by
tetherin would be poised to engage CD4 on target cells facilitating VS
and polysynapse formation and more rapid cell-to-cell spread as we
observedwith Vpu-defective HIV-1 (Jolly et al., 2010). Notably, we did
not detect any loss of viral infectivity of virus produced from T cells
when Vpu was absent and tetherin was unantagonized (Jolly et al.,
2010). By contrast HeLa cells or 293T cells transfected with plasmid-
encoding tetherin express higher levels of tetherin at the cell surface
(Miyagi et al., 2009; Neil et al., 2007, 2008; Van Damme et al., 2008).
When these cells were used as donor cells productive cell-to-cell
spread was inhibited due to the formation of unusually large viral
aggregates. Viral aggregates were transferred to target cells but
remained stuck at the cell surface and virus did not appear to fuseFig. 2. A proposed model for cell-to-cell spread of Vpu-defective HIV-1 in the presence of
different amounts of unantagonized tetherin on the surface of the virus-producing cell.
Under conditionswhere thedonor cell expresses lower levels of tetherin (e.g., endogenous
expression on T cells) cell-to-cell spread can occur and target T cells become productively
infected. When the donor cell expresses very high levels of tetherin (e.g., epithelial cells
such as HeLa cells or cells over-expressing plasmid-encoded tetherin) then virus could be
transferred as unusually large, tethered aggregates that cannot fuse appropriately at the
plasma membrane and productive infection would be blocked.appropriately at the plasma membrane, leading to reduced infectivity
(Casartelli et al., 2010) (Fig. 2). This effect may be explained by large
amounts of tetherin being incorporated into virions. A recent report
similarly observed an apparent reduction HIV-1 infectivity in the
presence of tetherin (Zhang and Liang, 2010); however in this study
virus was also produced from epithelial cells co-transfected with
tetherin-encoding plasmid therefore resulting in higher tetherin
expression that would be expected on T cells. It should be noted
that variations in tetherin expression have also been reported
between different T cell lines (Miyagi et al., 2009) and this too may
account for some of the discordant results in cell-to-cell spread when
T cells were used. It will be interesting to see if future studies probe
the infectivity of HIV-1 produced from infected T cells and if so,
whether they observe reduced infectivity or not in the presence of
tetherin.
Considering the chronicity of the infected cells, we generally used
cells later after initial infection in order to maximise the percentage
of infected cells used in our assays to obviate any effect of virus
spreading within the donor population in co-culture assays. It is
possible that allowing the infection to proceed for longer in T cells
could also increase the amount of proteolytically mature, infectious
virus tethered at the cell surface thus enhancing transmission of Vpu-
defective virus. Moreover, it is possible that longer incubations may
provide opportunity for cell-to-cell contacts to occur that could
induce budding but keep nascent virus trapped at the cell surface,
there by forming structures similar to tetherin-containing viral
bioﬁlms that have been shown to facilitate cell-to-cell spread of
HTLV-1 at VS (Pais-Correia et al., 2010). Using cells at earlier times
post-infection may result in less tethered virus accumulating at the
plasma membrane of T cells infected with Vpu-defective virus
resulting in reduced virus transfer. It may also be speculated that de
novo virus assembly at the VS may result in a shift in the balance of
immature vs. mature virions being transferred by cell-to-cell spread in
favour of non-infectious, immature virus.
It is interesting to note that neither HTLV-1 nor MLV encode
known tetherin antagonist but disseminate predominantly via cell-to-
cell spread. Recent evidence suggests that tetherin can partly reduce
MLV transmission in mouse cells by an as yet unknown mechanism
(Gofﬁnet et al., 2010b) but whether this is due to unidentiﬁed
antagonism by anMLV protein or another mechanism is unclear. Thus
it seems possible that HIV-1 may use different mechanisms under
certain conditions and that retroviruses may also be able to use
tetherin to its advantage in some situations. Moreover, it is also
possible that different cell-to-cell interactions (e.g., DC-T cell or
macrophage-T cell) may shift the balance towards transmission or
restriction by tetherin during cell-to-cell spread. Notably, T cell-to-
T cell spread is less sensitive to interferon-mediated inhibition
than cell-free infection suggesting that cell-to-cell transmission
can partially overcome interferon-induced blocks to transmission
(Vendrame et al., 2009). It is tempting to speculate that differences in
cell-to-cell versus cell-free spread in the presence or absence of
interferon may account for the variable results seen using interferon-
based therapy (Frissen et al., 1997; Hatzakis et al., 2001; Hulton et al.,
1992; Kaiser et al., 1992; Landau et al., 2000; Rivero et al., 1997;
Skillman et al., 1996; Sperber et al., 1993). Clearly more work is
needed to clarify this area and to more completely delineate the
different possible mechanism of HIV-1 cell-to-cell spread and how
tetherin may ﬁt into this.
Other interferon inducible cellular proteins can limit HIV-1 release
such as ISG15, a ubiquitin-like protein that inhibits ubiquitination of
Gag and Tsg101which arrests HIV-1 budding at a late stage (Okumura
et al., 2006) but whether ISG15 is similarly active against cell-to-cell
spread in unclear. Late-budding defects involving ESCRT are charac-
terized by the accumulation of immature virus at the cells surface and
immature HIV-1 is not infectious, thus is it likely that ISG15 would
interfere with cell-to-cell spread.
257C. Jolly / Virology 411 (2011) 251–259Concluding remarks
Innate immune activation and interferon secretion following
exposure of cells to retroviruses such as HIV-1 has important
consequences for immune regulation and is a double-edged sword
during HIV-1 infection (Chang and Altfeld, 2010). In the short term,
innate immune activation is necessary for recruitment of effector cells
and initiating adaptive immunity; however the recruitment of target T
cells and macrophages, for example to sites of virus infection, and
subsequent T cell activation increases the local pool of susceptible
target cells able to support robust viral replication. Moreover, chronic
immune activation will result in the loss of CD4+ T cells, homeostatic
inbalance and T cell exhaustion, increasing the risk of disease
progression and opportunistic infections. How cell-to-cell spread is
modulated by innate immunity and how viral dissemination maybe
counteracted by innate recognition is an emerging area of research
and further work is clearly needed to address the molecular
mechanisms of cell-to-cell spread in the context of innate immunity
and the role of interferon-induced restriction factors in this. Early
insights into what is a budding area of research, are turning out to be
intriguing and probably have consequences for therapeutic interven-
tion and future efforts to tackle HIV-1/AIDS.Acknowledgments
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